Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant candida species and aspergillus species isolates

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 2, 2014, Pages 1248-1251

  Jiménez Ortigosa, Cristina ^a   Paderu, Padmaja ^a   Motyl, Mary R ^b   Perlin, David S ^a  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BETA GLUCAN SYNTHASE; CASPOFUNGIN; ECHINOCANDIN; MK 3118; UNCLASSIFIED DRUG;

ARTICLE; ASPERGILLUS FUMIGATUS; CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOPSIS; CANDIDA TROPICALIS; CONTROLLED STUDY; DRUG EFFICACY; FUNGUS ISOLATION; IC 50; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; ASPERGILLUS; BETA-GLUCANS; CANDIDA; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; GLYCOSIDES; MICROBIAL SENSITIVITY TESTS; TRITERPENES;

EID: 84893490335     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02145-13     Document Type: Article

References (19)

1. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr, Calandra TF, Edwards JE, Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD; Infectious Diseases Society of America. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535. http://dx.doi.org/10.1086/596757.
2. Denning DW. 2003. Echinocandin antifungal drugs. Lancet 362:1142-1151. http://dx.doi.org/10.1016/S0140-6736(03)14472-8.
3. Perlin DS. 2007. Resistance to echinocandin-class antifungal drugs. Drug Resist. Updat. 10:121-130. http://dx.doi.org/10.1016/j.drup.2007.04.002.
4. Onishi J, Meinz M, Thompson J, Curotto J, Dreikorn S, Rosenbach M, Douglas C, Abruzzo G, Flattery A, Kong L, Cabello A, Vicente F, Pelaez F, Diez MT, Martin I, Bills G, Giacobbe R, Dombrowski A, Schwartz R, Morris S, Harris G, Tsipouras A, Wilson K, Kurtz MB. 2000. Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors. Antimicrob. Agents Chemother. 44:368-377. http://dx.doi.org/10.1128/AAC.44.2.368-377.2000.
5. Peel M, Fan W, Mamai A, Hong J, Orr M, Ouvry G, Perrey D, Liu H, Jones M, Nelson K, Ogbu C, Lee S, Li K, Kirwan R, Noe A, Sligar J, Martensen P, Balkove J, Greenlee CM, Meng D, Parker D, Wildonger K, Liberator P, Abruzzo G, Flattery A, Galgoci A, Giacobbe R, Gill C, Hsu MJ, Misura A, Nielsen J, Powles M, Racine F, Dragovic J, Habulihaz B, Balkovec J. 2010. Enfumafungin derivatives: orally active glucan synthase inhibitors, abstr F1-845. Abstr. Intersci. Conf. Antimicrob. Agents Chemother., Boston, M.A.
6. Motyl MR, Tan C, Liberator P, Giacobbe R, Racine F, Hsu MJ, Nielsen-Kahn, Bowman JJ, Douglas C, Hammond M, Balkovec JM, Greenlee ML, Meng D, Parker D, Peel M, Fan W, Mamai A, Hong J, Orr M, Ouvry G, Perrey D, Liu H, Jones M, Nelson K, Ogbu C, Lee S, Li K, Kirwan R, Noe A, Sligar J, Martensen P. 2010. Abstr. Intersci. Conf. Antimicrob. Agents Chemother., Boston, MA, abstr F1-847.
7. Flattery A, Abruzzo G, Gill C, Powles M, Misura A, Galgoci A, Colwell L, Dragovic J, Tong X, Wolff M, Liberator P. 2010. Abstr. Intersci. Conf. Antimicrob. Agents Chemother., Boston, MA, abstr F1-848.
8. Flattery A, Abruzzo G, Gill C, Powles M, Misura A, Galgoci A, Douglas C, Hawkins J, Galuska S, Pereira T, Tong S, Wolff M, Song Q, Liberator P. 2010. Abstr. Intersci. Conf. Antimicrob. Agents Chemother., Boston, MA, abstr F1-849.
9. Rocha EM, Garcia-Effron G, Park S, Perlin DS. 2007. A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus. Antimicrob. Agents Chemother. 51:4174-4176. http://dx.doi.org/10. 1128/AAC.00917-07.
10. National Committee for Clinical Laboratory Standards. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. Clinical and Laboratory Standards Institute document M27-A3, 3rd ed, vol 2. National Committee for Clinical Laboratory Standards, Wayne, PA.
11. National Committee for Clinical Laboratory Standards. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard. Clinical and Laboratory Standards Institute document M38-A2, 2nd ed, vol 2. National Committee for Clinical Laboratory Standards, Wayne, PA.
12. Pfaller MA, Messer SA, Motyl MR, Jones RN, Castanheira M. 2013. Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST). J. Antimicrob. Chemother. 68:858-863. http://dx.doi.org/10.1093/jac/dks466.
13. Hajdu R, Thompson R, Sundelof JG, Pelak BA, Bouffard FA, Dropinski JF, Kropp H. 1997. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob. Agents Chemother. 41:2339-2344.
14. Paderu P, Garcia-Effron G, Balashov S, Delmas G, Park S, Perlin DS. 2007. Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob. Agents Chemother. 51:2253-2256. http://dx.doi.org/10.1128/AAC.01536- 06.
15. Garcia-Effron G, Park S, Perlin DS. 2011. Improved detection of Candida sp. fks hot spot mutants by using the method of the CLSI M27-A3 document with the addition of bovine serum albumin. Antimicrob. Agents Chemother. 55:2245-2255. http://dx.doi.org/10.1128/AAC.01350-10.
16. Odabasi Z, Paetznick V, Rex JH, Ostrosky-Zeichner L. 2007. Effects of serum on in vitro susceptibility testing of echinocandins. Antimicrob. Agents Chemother. 51:4214-4216. http://dx.doi.org/10.1128/AAC.01589-06.
17. Pfaller MA, Messer SA, Motyl MR, Jones RN, Castanheira M. 2013. In vitro activitity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods. Antimicrob. Agents Chemother. 57:1065-1068. http://dx.doi.org/10.1128/AAC.01588-12.
18. Garcia-Effron G, Lee S, Park S, Cleary JD, Perlin DS. 2009. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob. Agents Chemother. 53:3690-3699. http://dx.doi.org/10.1128/AAC.00443-09.
19. Garcia-Effron G, Park S, Perlin DS. 2009. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob. Agents Chemother. 53:112-122. http://dx.doi.org/10.1128/AAC.01162-08.